secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001104659-24-119941
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Q3 cash $34.3M; raised $19.4M with potential $73.3M; positive WM data supports NDA
--------------------------------------------------------------------------------

- Cash $34.3M at Sept 30, 2024, up from $9.6M at Dec 31, 2023; raised $19.4M from warrant exercises with potential for additional $73.3M.
- Q3 R&D expenses $5.5M (down from $7.0M YoY) due to end of WM pivotal enrollment; G&A $7.8M (up from $2.4M YoY) for commercialization prep.
- Positive Phase 2 CLOVER-WaM results for iopofosine I 131 in WM; planning near-term NDA submission for accelerated approval.
- Data selected for oral presentation at ASH meeting on Dec 9, 2024.
- Entered supply agreements (SpectronRx, Northstar) and collaboration with City of Hope for mycosis fungoides.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/0001104659-24-119941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924119941/tm2428692d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer